Concepedia

Samuel Chackalamannil

SC

58

Publications

2.2K

Citations

27

H-Index

1982

Active since

Affiliations

AIL Research (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Duke University

Samuel Chackalamannil is an author at AIL Research (United States) specializing in medicine, drug discovery, and pharmacology.

ORCID

Top concepts

Publications per year

1982–2018

58

Publications

58

Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity

Samuel Chackalamannil, Yuguang Wang, William J. Greenlee et al. · Journal of Medicinal Chemistry · 2008 · 267 citations · Full text

, , +21

Discovery of Potent Orally Active Thrombin Receptor (Protease Activated Receptor 1) Antagonists as Novel Antithrombotic Agents

Samuel Chackalamannil, Yan Xia, William J. Greenlee et al. · Journal of Medicinal Chemistry · 2005 · 123 citations · Full text

, , +18

Design and synthesis of piperidinyl piperidine analogues as potent and selective M2 muscarinic receptor antagonists

Yuguang Wang, Samuel Chackalamannil, Zhiyong Hu et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 96 citations · Full text

, , +5

A Highly Efficient Total Synthesis of (+)-Himbacine

Samuel Chackalamannil, Robert J. Davies, Theodros Asberom et al. · Journal of the American Chemical Society · 1996 · 85 citations

, , +12

Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity

Ho-Sam Ahn, Ana Bercovici, George Boykow et al. · Journal of Medicinal Chemistry · 1997 · 80 citations · Full text

Rows per page

1–5 of 58